Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
Top Cited Papers
Open Access
- 15 July 2018
- journal article
- research article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 17 (1), 139-147
- https://doi.org/10.1016/j.cgh.2018.07.009
Abstract
No abstract availableKeywords
Funding Information
- Pfizer Inc
This publication has 16 references indexed in Scilit:
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2014
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2013
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialThe Lancet, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2011
- Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitisAlimentary Pharmacology & Therapeutics, 2009
- Treatment of ulcerative colitis from the patient’s perspective: a survey of preferences and satisfaction with therapyAlimentary Pharmacology & Therapeutics, 2009
- American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel DiseaseGastroenterology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisThe New England Journal of Medicine, 1987